Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 14, 2025; 31(42): 111708
Published online Nov 14, 2025. doi: 10.3748/wjg.v31.i42.111708
Published online Nov 14, 2025. doi: 10.3748/wjg.v31.i42.111708
Unveiling Yiyi Fuzi Baijiang powder: Microecological and network pharmacology approach to ulcerative colitis treatment
Liang-Kun Zhang, Jian Chen, Jinan Central Hospital Affiliated to Shandong First Medical University, Jinan 250355, Shandong Province, China
Wen-Chao Gu, Shandong University of Traditional Chinese Medicine, Jinan 250355, Shandong Province, China
Wen-Chao Gu, Jinan Central Hospital Affiliated to Shandong First Medical University, College of Traditional Chinese Medicine, Jinan 250355, Shandong Province, China
Jian Chen, State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Beijing 100700, China
Co-first authors: Liang-Kun Zhang and Wen-Chao Gu.
Author contributions: Chen J designed and coordinated the study; Zhang LK and Gu WC performed the experiments, acquired and analyzed data; Zhang LK interpreted the data; Zhang LK and Gu WC wrote the manuscript; all authors approved the final version of the article.
Supported by Key Project at Central Government Level, No. 2060302; Key Project of Traditional Chinese Medicine Science and Technology in Shandong Province, No. Z-2023015; and Clinical Medical Science and Technology Innovation Program of Jinan Science and Technology Bureau, No. 202328043.
Institutional review board statement: This study does not involve any human experiments.
Institutional animal care and use committee statement: All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of the Shandong University of Traditional Chinese Medicine (No. SDUTCM20191015101).
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Data sharing statement: All the data obtained in the current study are available from the corresponding authors upon reasonable request.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jian Chen, MD, PhD, Jinan Central Hospital Affiliated to Shandong First Medical University, No. 105 Jiefang Road, Lixia District, Jinan 250355, Shandong Province, China. chenjian860103@163.com
Received: July 14, 2025
Revised: August 6, 2025
Accepted: October 11, 2025
Published online: November 14, 2025
Processing time: 124 Days and 16.5 Hours
Revised: August 6, 2025
Accepted: October 11, 2025
Published online: November 14, 2025
Processing time: 124 Days and 16.5 Hours
Core Tip
Core Tip: The therapeutic application of Yiyi Fuzi Baijiang powder (YFB) for ulcerative colitis (UC) extends beyond merely altering the structure and abundance of gut microbiota. Instead, it aims to restore dynamic equilibrium by comprehensively modulating the intestinal microecological balance, thereby facilitating disease recovery. Furthermore, it is hypothesized that YFB powder may exert its effects on UC through potential mechanisms involving the NFKB1, RELA, and nuclear factor kappa B inhibitor alpha regulatory pathways, as well as the cancer and adipocytokine signaling pathways.